ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0270

Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis

Kristin Schmiedeberg1, Irene Abela2, Nicolas Vuilleumier3, Johannes von Kempis4 and Andrea Rubbert-Roth5, 1Cantonal Hospital St Gallen, St.Gallen, Switzerland, 2Institute of Medical Virology, University of Zurich, Zürich, Switzerland, 3Laboratory Medicine Division, University of Geneva, Geneva, Switzerland, 4Division of Rheumatology, Cantonal Hospital St.Gallen, St. Gallen, Switzerland, 5Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland

Meeting: ACR Convergence 2022

Keywords: COVID-19, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Anti-SARS-CoV2 mRNA vaccination may result in blunted humoral immune responses with lower peak titers and a different kinetic in patients with rheumatic diseases receiving immunomodulatory therapies compared to healthy controls1.

Vaccine-induced humoral immune responses will elicit IgM and IgA responses and an isotype class switch is required to establish robust IgG responses directed against different viral antigens. We hypothesize that lower peak titers of vaccine-induced anti-S1 result from a delayed isotype switch in RA patients on immunomodulatory treatment

Methods: We seek to analyse the ratio of IgG to IgM and IgG to IgA that may be regarded as a surrogate for a delayed isotype class switching after vaccination with anti-SARS-CoV-2 mRNA-based vaccines in patients with rheumatoid arthritis.

We prospectively analysed RA patients and HC after receiving mRNA anti-SARS-CoV-2 vaccines. Blood sampling was performed before (T0) the first vaccine dose, three weeks (T1) and six weeks (T2) after the first dose, and after 12 (T3) and 24 weeks (T4). Humoral immune responses (IgG, IgA and IgM) to four different SARS-CoV-2 antigens (receptor binding domain (RBD), spike glycoprotein subunits S1 and S2, and nucleocapsid protein (NP) were determined by using the multiplex immunoassay ABCORA.1

Results: We longitudinally assessed the isotypic humoral immune responses against four SARS-CoV-2 antigens in 21 healthy controls (HC) and 73 RA patients on DMARD therapy following a standard two dose regimen of mRNA based anti-SARS-CoV2 vaccines. HC showed a rapid increase of IgG/IgM ratio two weeks after the second vaccine dose. Overall IgG/IgM and IgG/IgA ratios were significantly lower in RA patients and involving immune responses to S1 and RBD (Fig.1). Patients treated with abatacept, JAK inhibitors and anti-cytokine (TNFa, IL-6, IL-1) biologics in combination with csDMARDs were more likely to develop a delayed IgM/IgG isotype switch that resulted in a delayed and decreased IgG response (Table 1).

Conclusion: This study provides insights into the attenuated immune response following an mRNA based anti-SARS-CoV-2 vaccination in patients with RA. The decreased immune response after the first dose of an mRNA based SARS-CoV-2 vaccine with an enhanced immune response to subsequent doses is in line with the assumption of a delayed isotype class switch from IgM to IgG.

References 1. Abela IA. 2021. Nat Commun 12: 6703

Supporting image 1

Figure 1 Antibody kinetic of vaccinated RA patients and healthy controls for antibodies IgG/IgM and IgA/IgM ratio
Boxplots showing antibodies IgG/IgM ratio for S1 (A, C) and RBD (B, D) isotype as determined by Elecsys Anti-SARS-CoV_2 (S) assay at 3, 6 and 12 weeks following the first vaccine dose in HC and RA patients. T0=baseline, T1=3 weeks after 1st vaccination, T2=2 weeks after 2nd vaccination, T3=12 weeks after 1st vaccination, T4= 24 weeks after 1st vaccination.

Supporting image 2


Disclosures: K. Schmiedeberg, None; I. Abela, None; N. Vuilleumier, None; J. von Kempis, None; A. Rubbert-Roth, None.

To cite this abstract in AMA style:

Schmiedeberg K, Abela I, Vuilleumier N, von Kempis J, Rubbert-Roth A. Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/lower-mrna-anti-sars-cov2-induced-igg-antibody-responses-to-s1-s2-and-rbd-may-result-from-a-delayed-iga-and-igm-class-switch-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lower-mrna-anti-sars-cov2-induced-igg-antibody-responses-to-s1-s2-and-rbd-may-result-from-a-delayed-iga-and-igm-class-switch-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology